Cornelia Yzer

Cornelia Yzer advises domestic and foreign companies on mergers and acquisitions and on regulatory issues, making them benefit from her many years of experience in industry and in government positions. A particular industry focus is life science and the digital economic. At Luther, Cornelia Yzer coordinates the Health Care & Life Science sector and the practice group Digital Health. Furthermore, Cornelia Yzer advises her clients on all aspects of research funding.

IT Law
Corporate/M&A
Environment & Planning Law, Regulatory

Cornelia Yzer not only has many years of experience as a lawyer but also demonstrable expertise as a manager, chairwoman/member of supervisory boards of companies and major research institutions and also from government positions.

In the past, she inter alia held the following positions:

• Executive employee at Bayer AG
• Chief Managing Director of the German Association of Research-based Pharmaceutical Companies (vfa) (1997-2012)
• Member of the German Parliament (1990-1998), Parliamentary State Secretary at the Federal Ministry for Education, Science, Research and Technology, and Senator for Business, Research and Technology of the State of Berlin
• Chairwoman of the Administrative Board of Investitionsbank Berlin, Chairwoman of the Supervisory Board of BWB, Member of the Strategic Advisory Board of Medidata Inc., New York (USA), Member of the European Advisory Board of the medical products manufacturer Guidant
• Chairwoman of the Boards of Trustees of major research institutions (German Cancer Research Centre (DKFZ), Max Delbrück Centre for Molecular Medicine (MDC))
• Board Member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

Cornelia Yzer studied law and business at the Universities of Bochum and Münster (both Germany). She was admitted to the German Bar in 1990.

• The Legal 500 Germany (2020): Mentioned in Industry Focus - Health

• Advising a German vaccine producer on the conclusion of an agreement with the Coalition for Epidemic Preparedness (CEPI) regarding the development of a pandemic vaccine
• Advising a Spanish drug manufacturer on an asset deal in Germany
• Advising a British provider of medical cannabis on an acquisition in Germany
• Advising an Australian provider of medical cannabis on market access in Germany
• Advising an international personnel services provider on the conclusion of agreements with companies from the pharmaceuticals industry

• Market Study Medical Technology 2020
• BBC-Statement zu den gestrigen Beschlüssen des EU-Sondergipfels zum Brexit
• Brexit and its impact on the Life Science Industry
• Viva Vivy! Die digitale Gesundheits-App - Digital Healthcare und der Datenschutz
• Neue Datenschutz-Pflichten für Arbeitgeber
• Das eHealth-Datenschutz-Labyrinth
• Mittelstand braucht Digitalisierung

• Over EUR 4 billion for the digitalisation of hospitals German Parliament passes Future of Hospitals Act (Krankenhauszukunftsgesetz–KHZG)
• Federal Government calls for the regional production of urgently needed masks and protective gowns
• EU Commission recommends simplified conformity assessment and market surveillance procedures for much needed personal protective equipment and other medical devices
• Commencement date of the new medical devices regulation to be suspended for one year
• COVID-19 pandemic requires pragmatic approach regarding the implementation of the EU Medical Devices Regulation
• Gesundheits-Apps auf dem Vormarsch - Welche Hürden müssen digitale Gesundheitsanwendungen nehmen für eine Erstattungsfähigkeit bzw. Aufnahme in das „DiGA-Verzeichnis“?